- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05726994
Volatilomic Approaches for the Study of CFTR Modulators (VOLATIL-CF) (VOLATIL-CF)
Volatilomic Approaches for the Study of CFTR Modulators
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This is a single-center prospective cohort study that plans to include 20 children with cystic fibrosis aged 6 to 12 years old who will initiate Kaftrio® in early 2023.
The children will be monitored for one month; three visits are planned as part of routine care (before initiation of treatment, in the course of the first week and after one month of treatment) during which exhaled breath collection and analysis will also be performed. Access to clinical data collected throughout routine follow-up of these children (analysis of induced sputum, urine and blood, sweat test, respiratory function tests) will be granted upon patient/parent authorization.
Study Type
Enrollment (Anticipated)
Contacts and Locations
Study Contact
- Name: Charlotte ROY, Doctor
- Phone Number: +33 1 44 49 44 92
- Email: charlotte.roy@aphp.fr
Study Locations
-
-
Ile-de-France
-
Paris, Ile-de-France, France, 75015
- Recruiting
- Hopital Necker - Enfants Malades
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Patients with cystic fibrosis initiating Kaftrio® treatment.
- Patients and holders of parental authority not opposing participation in this research.
- Patients affiliated to a Health Insurance system or beneficiaries. Exclusion Criteria
- Patients deprived of liberty or under guardianship.
- Pregnant or breastfeeding patients.
- Lung transplanted patients.
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
cystic fibrosis and Kaftrio®
20 children with cystic fibrosis aged 6 to 12 who initiate Kaftrio®
|
Fasting children will be asked to breathe normally through a mouthpiece for the collection and analysis of exhaled breath.
Clinical data will be collected in order to seek correlations with the exhaled breath profile.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
volatile organic compounds (VOC) profile
Time Frame: At 0 day, 7 days, and 1 month of treatment
|
identification of VOCs in exhaled breath with a significant variation between 0 day, 7 days, and/or 1 month of treatment
|
At 0 day, 7 days, and 1 month of treatment
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Weight
Time Frame: At 0 day, 7 days, and 1 month of treatment
|
Weight measured at visits
|
At 0 day, 7 days, and 1 month of treatment
|
Sweat test
Time Frame: At 0 day, 7 days, and 1 month of treatment
|
Sweat test result
|
At 0 day, 7 days, and 1 month of treatment
|
Induced sputum - microbiology
Time Frame: At 0 day, 7 days, and 1 month of treatment
|
Results of microbiological analysis of induced sputum
|
At 0 day, 7 days, and 1 month of treatment
|
Induced sputum - immunology
Time Frame: At 0 day, 7 days, and 1 month of treatment
|
Results of inflammatory markers analysis of induced sputum (neutrophil elastase, IL-8, IL-1b, IL-6)
|
At 0 day, 7 days, and 1 month of treatment
|
Spirometry
Time Frame: At 0 day, 7 days, and 1 month of treatment
|
Results of spirometry FVC measurements
|
At 0 day, 7 days, and 1 month of treatment
|
Spirometry
Time Frame: At 0 day, 7 days, and 1 month of treatment
|
Results of spirometry FEV1 measurements
|
At 0 day, 7 days, and 1 month of treatment
|
Spirometry
Time Frame: At 0 day, 7 days, and 1 month of treatment
|
Results of spirometry DEM25-75 measurements
|
At 0 day, 7 days, and 1 month of treatment
|
Urine
Time Frame: At 0 day and 1 month of treatment
|
Biobanking for metabolic study
|
At 0 day and 1 month of treatment
|
Blood
Time Frame: At 0 day and 1 month of treatment
|
Biobanking for metabolic study
|
At 0 day and 1 month of treatment
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- APHP221173
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cystic Fibrosis
-
Hospital de Clinicas de Porto AlegreUnknownCystic Fibrosis | Cystic Fibrosis Pulmonary Exacerbation | Cystic Fibrosis in Children | Cystic Fibrosis With ExacerbationBrazil
-
University of Colorado, DenverCystic Fibrosis FoundationTerminatedCystic Fibrosis-related Diabetes | Cystic Fibrosis Pulmonary Exacerbation | Cystic Fibrosis in ChildrenUnited States
-
Royal College of Surgeons, IrelandThe Hospital for Sick Children; Imperial College London; Erasmus Medical Center; University College Dublin and other collaboratorsActive, not recruitingCystic Fibrosis | Adherence, Medication | Cystic Fibrosis Gastrointestinal Disease | Cystic Fibrosis in Children | Cystic Fibrosis Liver DiseaseUnited Kingdom, Ireland
-
Herlev and Gentofte HospitalCopenhagen University Hospital, DenmarkActive, not recruitingMyocardial Infarction | Heart Diseases | Heart Failure | Stroke | Cystic Fibrosis | Heart Failure, Diastolic | Heart Failure, Systolic | Left Ventricular Dysfunction | Cystic Fibrosis-related Diabetes | Cystic Fibrosis Gastrointestinal Disease | Cystic Fibrosis of Pancreas | Cystic Fibrosis, Pulmonary | Cystic...Denmark
-
The Hospital for Sick ChildrenCanadian Cystic Fibrosis FoundationActive, not recruitingCystic Fibrosis | Cystic Fibrosis Gastrointestinal Disease | Cystic Fibrosis in ChildrenCanada
-
Arrowhead PharmaceuticalsTerminatedCystic Fibrosis, PulmonaryAustralia, New Zealand
-
AzurRx SASCompletedCystic Fibrosis | Cystic Fibrosis Gastrointestinal Disease | Cystic Fibrosis of PancreasTurkey, Hungary
-
Dartmouth-Hitchcock Medical CenterTrustees of Dartmouth CollegeWithdrawnCystic Fibrosis-related Diabetes | Cystic Fibrosis Liver Disease | CF - Cystic FibrosisUnited States
-
University Hospital, BordeauxCompleted
-
University of PortsmouthUniversity Hospital Southampton NHS Foundation Trust; Loughborough University; Queen Alexandra HospitalTerminated
Clinical Trials on exhaled breath collection
-
Seoul National University HospitalUnknownGastrointestinal Hemorrhage | Volatile Organic CompoundsKorea, Republic of
-
Rambam Health Care CampusTechnion, Israel Institute of TechnologyCompletedParkinson's Disease | Parkinsonism
-
University of California, DavisNational Heart, Lung, and Blood Institute (NHLBI)CompletedUpper Respiratory Tract Infections, Asthma, Exhaled BreathUnited States
-
Wake Forest University Health SciencesNational Cancer Institute (NCI)TerminatedNonsmall Cell Lung Cancer Stage III | PneumonitisUnited States
-
Jena University HospitalCompletedPneumonia, Ventilator-associatedGermany
-
Landon Pediatric FoundationCompletedBacterial InfectionsUnited States
-
University of Massachusetts, WorcesterTerminatedCough | Gastroesophageal RefluxUnited States
-
Prof. Dr. Jens HohlfeldHannover Medical SchoolCompletedChronic Lung Allograft Dysfunction (CLAD)Germany
-
National Heart Centre SingaporeRecruiting
-
Ospedale San RaffaeleRecruiting